OTCMKTS:MLLCF Molecular Partners (MLLCF) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free MLLCF Stock Alerts $3.80 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.80▼$3.8050-Day Range$3.80▼$4.4552-Week Range$3.40▼$7.22VolumeN/AAverage Volume786 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Molecular Partners alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Molecular Partners Stock (OTCMKTS:MLLCF)Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Read More MLLCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLLCF Stock News HeadlinesApril 17, 2024 | finance.yahoo.comMolecular Partners Announces All Board Proposals Approved at the Annual General MeetingMarch 14, 2024 | msn.comMolecular Partners GAAP EPS of -$1.89 beats by $0.14, revenue of $7.0M beats by $1.93MApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. March 12, 2024 | finance.yahoo.comExpert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor ProgramMarch 1, 2024 | marketwatch.comMolecular Partners Gets Investor Class Action TossedFebruary 9, 2024 | investing.comMolecular Partners AG (MOLN)February 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for 4D Molecular Therapeutics on Promising Wet AMD Treatment Trial ResultsFebruary 6, 2024 | investing.comMolecular Partners AG ADR (MOLN)April 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. February 4, 2024 | msn.comScientists found a major clue why 4 of 5 autoimmune patients are womenFebruary 4, 2024 | msn.comPenn names new chief innovation officer, aiming to expand a multibillion-dollar windfall from faculty researchJanuary 5, 2024 | finance.yahoo.comMolecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin TherapiesDecember 22, 2023 | finance.yahoo.comRetail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%December 14, 2023 | finance.yahoo.comMolecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesNovember 27, 2023 | msn.comMolecular Partners AG - ADR (MOLN) Price Target Increased by 12.87% to 10.29November 27, 2023 | msn.comMolecular Partners (MLLCF) Price Target Increased by 21.13% to 10.71November 14, 2023 | sg.finance.yahoo.comMolecular Partners AG (MOLN.SW)November 14, 2023 | finance.yahoo.comMolecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)November 9, 2023 | finance.yahoo.comWe're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn RateNovember 6, 2023 | markets.businessinsider.comBuy Rating for 4D Molecular Therapeutics: An Analysis of Potential Growth and Future ProspectsNovember 3, 2023 | finance.yahoo.comMolecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingNovember 3, 2023 | finance.yahoo.comCompanion Animal Diagnostics Market Size to Hit 9.1% CAGR, Globally, by 2030 - Exclusive Report by The Insight PartnersOctober 26, 2023 | finance.yahoo.comMolecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioOctober 5, 2023 | finance.yahoo.comShareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years agoSeptember 13, 2023 | finance.yahoo.comMolecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual MeetingSeptember 3, 2023 | msn.comMolecular Partners (MLLCF) Price Target Decreased by 30.37% to 8.84August 11, 2023 | msn.comChardan Capital Reiterates 4D Molecular Therapeutics (FDMT) Buy RecommendationSee More Headlines Receive MLLCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MLLCF CUSIPN/A CIKN/A Webwww.molecularpartners.com Phone(144) 755-7700FaxN/AEmployees167Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Patrick Amstutz Ph.D. (Age 49)Co-Founder, CEO, Member of Management Board & Director Comp: $727.51kDr. Michael Tobias Stumpp Ph.D. (Age 52)Co-Founder, Executive VP of Projects & Member of Management Board Mr. Robert HendriksSenior VP of FinanceMr. Alexander Zurcher (Age 49)COO & Member of Management Board Ms. Renate Gloggner (Age 54)Executive VP of People & Community and Member of Management Board Mr. Daniel Steiner Ph.D.Senior Vice President of Research & TechnologyMr. Seth D. LewisSenior Vice President of Investor Relations, Communications & StrategyMr. Michael PitznerGeneral Counsel, Compliance Officer, Senior VP Legal & Business DevelopmentDr. Pamela A. Trail Ph.D. (Age 68)Strategic Consultant Ms. Anne Goubier D.V.M.Ph.D., Senior Vice President of Research & Early DevelopmentMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors MLLCF Stock Analysis - Frequently Asked Questions How have MLLCF shares performed in 2024? Molecular Partners' stock was trading at $4.30 on January 1st, 2024. Since then, MLLCF stock has decreased by 11.6% and is now trading at $3.80. View the best growth stocks for 2024 here. How do I buy shares of Molecular Partners? Shares of MLLCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MLLCF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
